Merck jumps as it starts $53-per-share tender offer for Terns acquisition
Merck shares are climbing after the company formally launched its cash tender offer to buy Terns Pharmaceuticals for $53 per share, advancing a $6.7 billion deal aimed at strengthening Merck’s hematology/oncology pipeline. The offer, started April 7, 2026, is expected to move the acquisition toward a Q2 close and refocus investors on post-Keytruda growth.
1. What’s moving the stock
Merck (MRK) is trading higher as investors react to the company’s formal commencement of a cash tender offer to purchase all outstanding shares of Terns Pharmaceuticals at $53.00 per share. The tender-offer launch is a key mechanical step in progressing the previously announced acquisition and signals the transaction is moving through closing conditions on schedule. (merck.com)
2. Deal terms and why it matters
Merck agreed to acquire Terns in an all-cash transaction valued at roughly $6.7 billion to expand its hematology pipeline with TERN-701, a chronic myeloid leukemia candidate. The acquisition is expected to close in Q2 2026, subject to typical tender conditions, and Merck has indicated it expects to record an approximately $5.8 billion charge tied to the deal in 2026 results. (merck.com)
3. What investors will watch next
Near-term focus shifts to tender participation levels and any amendments or timing updates as the offer progresses, alongside management commentary on how the Terns asset fits into Merck’s longer-term oncology strategy. Investors are also looking ahead to Merck’s next earnings report date and whether the company reiterates or adjusts its 2026 outlook as deal-related accounting flows through. (markets.financialcontent.com)